beta thalassemia major. Cooley anaemia Severe beta thalassaemia Thalassaemia: intermedia major
Conditions
Interventions
Intervention 1: quercetin,90 tablets,500mg,3 months, once a day after a meal. Intervention 2: starch placebo, 90 tablets,500 mg, 3 months, once a day after a meal.
Treatment - Drugs
Placebo
quercetin,90 tablets,500mg,3 months, once a day after a meal
starch placebo, 90 tablets,500 mg, 3 months, once a day after a meal
Sponsors
Vice chancellor for research, Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 30 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 18 to 30 year old male and female beta thalassemia major patients; Inclination to cooperate and signing the written informed consent; A minimum of 2 years of blood transfusion history; blood specimen collection 20 days after the last blood transfusion; Regular and peculiar iron-chelating therapy with desferrioxamine; Vitamin C supplement intake with desferrioxamine; Serum ferritin level between 2500 to 3500 ng/ml Exclusion criteria: Uncontrollable and life threatening complication due to due to the supplement intake; A change in type or amount of the iron chelator; Pregnancy or lactation; Splenectomy; Hepatitis infection and other metabolic or infectious diseases; Less than 80% compliance of supplement intake; Consumption of drugs that interfere with quercetin; Drinking more than 500 mg/day of beverages rich in flavonoids; Smoking or alcohol consumption
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Malone dialdehyde (MDA). Timepoint: before and after the intervention. Method of measurement: nmol/gHb, colorimetry.;Total antioxidant capacity (TAC). Timepoint: before and after the intervention. Method of measurement: mmol/L, colorimetry.;Superoxide dismutase (SOD). Timepoint: before and after the intervention. Method of measurement: U/gHb, colorimetry.;Glutathione peroxidase (GPx). Timepoint: before and after the intervention. Method of measurement: U/gHb, colorimetry. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum Fe. Timepoint: before and after the intervention. Method of measurement: spectrophotometry,µg/dl.;Serum transferrin. Timepoint: before and after the intervention. Method of measurement: immunoturbidometry, mg/dl.;Serum ferritin. Timepoint: before and after the intervention. Method of measurement: spectrophotometry, ng/ml.;Total antioxidant capacity (TIBC). Timepoint: before and after the intervention. Method of measurement: calorimetry, µg/dl.;Transferrin saturation. Timepoint: before and after the intervention. Method of measurement: formula, %.;Aspartate transaminase (AST). Timepoint: before and after the intervention. Method of measurement: enzymatic calorimetry, IU/L.;Alanin transaminase (ALT). Timepoint: before and after the intervention. Method of measurement: enzymatic calorimetry, IU/L.;Alkaline phosphatase (ALP). Timepoint: before and after the intervention. Method of measurement: enzymatic calorimetry, IU/L.;High-sensitivity C reactive protein (hs-CRP). Timepoint: before and after the intervention. Method of measurement: ELISA, µg/ml.;Tumor necrosis factor alpha (TNF). Timepoint: before and after the intervention. Method of measurement: Elisa, pg/ml. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Azita Azarkeivan
High Institute for Research and Education in Transfusion Medicine
Outcome results
None listed